Recent developments in imaging of multiple sclerosis

Neurologist

Volumn 17, Issue 4, 2011, Pages 185-204

  Poloni, Guy ^a   Minagar, Alireza ^c   Haacke, E Mark ^d   Zivadinov, Robert ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

brain atrophy; diffusion imaging; functional MRI; lesion pathology; magnetic resonance imaging; magnetization transfer imaging; multiple sclerosis; myelin water fraction; susceptibilityweighted imaging

Indexed keywords

BRAIN CORTEX LESION; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATION; DIFFUSION TENSOR IMAGING; EDEMA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; IMAGING SYSTEM; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SUSCEPTIBILITY WEIGHTED IMAGING; THREE DIMENSIONAL IMAGING;

ATROPHY; BRAIN; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; SENSITIVITY AND SPECIFICITY;

EID: 79960318686     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31821a2643     Document Type: Review

References (190)

1. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338: 278-285. (Pubitemid 28065253)
2. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992;32:758-766.
3. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 1998;50: 1282-1288. (Pubitemid 28240340)
4. Grossman RI, Gonzalez-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology. 1986;161:721-725. (Pubitemid 17200424)
5. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(Pt 4):927-939.
6. Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121(Pt 1):3-24. (Pubitemid 28045503)
7. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging. 2005;15: 10S-21S. (Pubitemid 43010528)
8. Bakshi R, Minagar A, Jaisani Z, et al. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2:277-303. (Pubitemid 40471438)
9. Filippi M, Rocca MA, Arnold DL, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol. 2006;13:313-325.
10. Benedict R, Bruce J, Dwyer M, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol. 2006;63:1301-1306. (Pubitemid 44379833)
11. Bo L, Geurts JJ, Mork SJ, et al. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl. 2006;183:48-50.
12. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236:254-260. (Pubitemid 40853320)
13. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J Neurol Sci. 2005;233:55-59. (Pubitemid 40804816)
14. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci. 2004;9:665-683. (Pubitemid 39043742)
15. Tubridy N, Barker GJ, Macmanus DG, et al. Three-dimensional fast fluid attenuated inversion recovery (3D fast FLAIR): a new MRI sequence which increases the detectable cerebral lesion load in multiple sclerosis. Br J Radiol. 1998;71:840-845. (Pubitemid 28391084)
16. Campi A, Pontesilli S, Gerevini S, et al. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology. 2000;42:669-675.
17. Moseley IF, Miller DH, Gass A. The contribution of magnetic resonance imaging to the assessment of optic nerve and spinal cord involvement in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(suppl 1):S15-S20. (Pubitemid 28274431)
18. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27: 455-461. (Pubitemid 44897861)
19. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 1998;121(Pt 3):495-503. (Pubitemid 28116346)
20. Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60:236-242. (Pubitemid 44182398)
21. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology. 1999;52:599-606. (Pubitemid 29075611)
22. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclero¬sis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999; 46:197-206. (Pubitemid 29382876)
23. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993;116(Pt 1): 135-146. (Pubitemid 23087039)
24. Ingle GT, Stevenson VL, Miller DH, et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain. 2003;126:2528-2536. (Pubitemid 37314440)
25. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47:1469-1476. (Pubitemid 26422538)
26. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158-164. (Pubitemid 34438881)
27. Miki Y, Grossman RI, Udupa JK, et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR imagesFlack of correlation between changes in T2 lesion volume and clinical findings. Radiology. 1999;213:395-399. (Pubitemid 29510584)
28. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125: 327-337. (Pubitemid 34127435)
29. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5:283-286. (Pubitemid 29405626)
30. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353:964-969. (Pubitemid 29132605)
31. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:141-147.
32. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44: 635-641. (Pubitemid 24129988)
33. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15:239-245. (Pubitemid 34596884)
34. Rocca MA, Filippi M. Functional MRI in multiple sclerosis. J Neuroimaging. 2007;17(suppl 1):36S-41S. (Pubitemid 46558267)
35. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003;60:1073-1081. (Pubitemid 36975794)
36. Miller DH, Johnson G, Tofts PS, et al. Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. Magn Reson Med. 1989;11: 331-336. (Pubitemid 19225569)
37. Larsson HB, Frederiksen J, Petersen J, et al. Assessment of demyelination, edema, and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. Magn Reson Med. 1989;11:337-348. (Pubitemid 19225570)
38. Larsson HB, Frederiksen J, Kjaer L, et al. In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis. Magn Reson Med. 1988;7:43-55.
39. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46: 747-754. (Pubitemid 29518136)
40. Rumbach L, Armspach JP, Gounot D, et al. Nuclear magnetic resonance T2 relaxation times in multiple sclerosis. J Neurol Sci. 1991;104:176-181.
41. Naruse S, Horikawa Y, Tanaka C, et al. Proton nuclear magnetic resonance studies on brain edema. J Neurosurg. 1982;56: 747-752. (Pubitemid 12045500)
42. Barnes D, McDonald WI, Landon DN, et al. The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain. 1988;111(Pt 1):83-94.
43. Filippi M, Barker GJ, Horsfield MA, et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol. 1994;241:246-251. (Pubitemid 24072938)
44. Kidd D, Barker GJ, Tofts PS, et al. The transverse magnetisation decay characteristics of longstanding lesions and normal-appear¬ing white matter in multiple sclerosis. J Neurol. 1997;244: 125-130. (Pubitemid 27057959)
45. Barnes D, Munro PM, Youl BD, et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain. 1991;114(Pt 3):1271-1280.
46. Filippi M. Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler. 2000;6:320-326.
47. Hawkins CP, Mackenzie F, Tofts P, et al. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain. 1991;114(Pt 2):801-810.
48. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783-793. (Pubitemid 27481551)
49. Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003;60:640-646. (Pubitemid 36246083)
50. Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler. 2001;7:75-82. (Pubitemid 32514520)
51. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 1998;43:332-339. (Pubitemid 28113596)
52. Weiner HL, Guttmann CR, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol. 2000;104: 164-173. (Pubitemid 30125407)
53. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain. 1996;119(Pt 3):709-714. (Pubitemid 26237170)
54. Filippi M, Rovaris M, Gasperini C, et al. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis. J Neuroimaging. 1998;8:88-93. (Pubitemid 28217138)
55. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 1997;49:1682-1688. (Pubitemid 28015137)
56. Filippi M, Horsfield MA, Hajnal JV, et al. Quantitative assessment of magnetic resonance imaging lesion load in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(suppl 1):S88-S93. (Pubitemid 28274445)
57. Silver N, Lai M, Symms M, et al. Serial gadolinium-enhanced and magnetization transfer imaging to investigate the relationship between the duration of blood-brain barrier disruption and extent of demyelination in new multiple sclerosis lesions. J Neurol. 1999;246:728-730. (Pubitemid 29417860)
58. Erskine MK, Cook LL, Riddle KE, et al. Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci. 2005;32:205-212. (Pubitemid 40839963)
59. Sicotte NL, Voskuhl RR, Bouvier S, et al. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol. 2003;38:423-427. (Pubitemid 36791336)
60. Roychowdhury S, Maldjian JA, Grossman RI. Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. AJNR Am J Neuroradiol. 2000;21:869-874. (Pubitemid 30262833)
61. Minneboo A, Uitdehaag BM, Ader HJ, et al. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology. 2005;65:56-61. (Pubitemid 40967776)
62. Leist TP, Gobbini MI, Frank JA, et al. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol. 2001;58:57-60. (Pubitemid 32053208)
63. Morgen K, Jeffries NO, Stone R, et al. Ring-enchancement in multiple sclerosis: marker of disease severity. Mult Scler. 2001;7:167-171. (Pubitemid 32651816)
64. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19:675-683. (Pubitemid 30422711)
65. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126:1782-1789. (Pubitemid 36917337)
66. Silver NC, Lai M, Symms MR, et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology. 1998;51:758-764. (Pubitemid 28449256)
67. Filippi M. Magnetization transfer imaging to monitor the evolution of multiple sclerosis. Ital J Neurol Sci. 1999;20: S232-S240.
68. van Walderveen MA, Truyen L, van Oosten BW, et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol. 1999;56:345-351. (Pubitemid 29120233)
69. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009; 65:268-275.
70. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology. 2001;57:2185-2190. (Pubitemid 34016449)
71. Losseff NA, Miller DH, Kidd D, et al. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis: preliminary results. Mult Scler. 2001;7:23-25. (Pubitemid 32396575)
72. Sailer M, Losseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol. 2001;8:37-42. (Pubitemid 32154572)
73. Bink A, Schmitt M, Gaa J, et al. Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results. Eur Radiol. 2006;16:1104-1110.
74. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology. 2007;68: S72-S82. (Pubitemid 46848615)
75. Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 2007;28: 54-59. (Pubitemid 46147534)
76. Moraal B, Roosendaal SD, Pouwels PJ, et al. Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol. 2008;18:2311-2320.
77. Calabrese M, Filippi M, Rovaris M, et al. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage. 2008;42:1324-1328.
78. Roosendaal SD, Moraal B, Pouwels PJ, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler. 2009;15:708-714.
79. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66: 1144-1150.
80. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315-320.
81. Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003;9:323-331. (Pubitemid 36958014)
82. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389-400. (Pubitemid 32848742)
83. Bakshi R, Dmochowski J, Shaikh ZA, et al. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci. 2001;185:19-26. (Pubitemid 32215497)
84. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegenera-tion in multiple sclerosis. Ann Neurol. 2002;52:650-653.
85. Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain. 1999;122(Pt 1):17-26. (Pubitemid 29046269)
86. Bagnato F, Butman JA, Gupta S, et al. In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. AJNR Am J Neuroradiol. 2006;27:2161-2167. (Pubitemid 44788650)
87. Schmierer K, Parkes HG, So PW, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain. 2010;133:858-867.
88. Mainero C, Benner T, Radding A, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology. 2009;73:941-948.
89. Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol. 2006;27:1794-1798. (Pubitemid 44413574)
90. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11): 2059-2069. (Pubitemid 27493740)
91. Wattjes MP, Harzheim M, Lutterbey GG, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol. 2008;255:1159-1163.
92. Di Perri C, Dwyer MG, Wack DS, et al. Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls: a morphological and spatial quantitative comparison study. Neuroimage. 2009;47:1352-1362.
93. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705-2712. (Pubitemid 41552953)
94. Kangarlu A, Bourekas EC, Ray-Chaudhury A, et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol. 2007;28:262-266. (Pubitemid 46281042)
95. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev. 2004;46:261-281. (Pubitemid 39574328)
96. Xu S, Jordan EK, Brocke S, et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation. J Neurosci Res. 1998;52:549-558. (Pubitemid 28252736)
97. Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental auto¬immune encephalomyelitis. AJNR Am J Neuroradiol. 1999;20: 223-227. (Pubitemid 30418702)
98. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006;27:1000-1005. (Pubitemid 44897675)
99. Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain. 2008;131: 800-807. (Pubitemid 351294725)
100. Vellinga MM, Vrenken H, Hulst HE, et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging. 2009;29: 774-779.
101. Pirko I, Johnson A, Gamez J, et al. Disappearing "T1 black holes" in an animal model of multiple sclerosis. Front Biosci. 2004;9:1222-1227. (Pubitemid 39060838)
102. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158-170. (Pubitemid 43107851)
103. Zivadinov R, Reder A, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71:136-144.
104. Zivadinov R, Bakshi R. Brain and Spinal Cord Atrophy in Multiple Sclerosis. Hauppage, NY: Nova Biomedical Books; 2004:196.
105. Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging. 2006;23:605-618.
106. Evangelou N, DeLuca GC, Owens T, et al. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain. 2005;128:29-34. (Pubitemid 40070517)
107. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59: 1412-1420. (Pubitemid 35285996)
108. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging. 2004;14: 27S-35S. (Pubitemid 38781409)
109. Dastidar P, Heinonen T, Lehtimaki T, et al. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci. 1999; 165:36-42. (Pubitemid 29298079)
110. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain. 1996;119(Pt 6): 2009-2019.
111. Bermel RA, Sharma J, Tjoa CW, et al. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci. 2003;208:57-65. (Pubitemid 36294155)
112. Benedict RH, Weinstock-Guttman B, Fishman I, et al. Prediction of neuropsychological impairment in multiple sclerosis: compar¬ison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004;61:226-230. (Pubitemid 38197556)
113. Lin X, Tench CR, Evangelou N, et al. Measurement of spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14: S20-S26.
114. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000; 214:665-670. (Pubitemid 30115361)
115. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008;64:247-254.
116. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64: 255-265.
117. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101-1107. (Pubitemid 38623045)
118. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60:1157-1162. (Pubitemid 36418778)
119. Valsasina P, Benedetti B, Rovaris M, et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology. 2005;65:1126-1128. (Pubitemid 41429650)
120. Benedict RH, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler. 2007;13:722-730. (Pubitemid 47074094)
121. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multi¬ple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry. 2008;79:407-414. (Pubitemid 351441496)
122. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain. 2005;128:1454-1460. (Pubitemid 40826197)
123. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med. 1989;10:135-144. (Pubitemid 19107973)
124. van Buchem MA, Tofts PS. Magnetization transfer imaging. Neuroimaging Clin N Am. 2000;10:771-788, ix. (Pubitemid 32391267)
125. Filippi M, Rocca MA. Magnetization transfer magnetic reso¬nance imaging in the assessment of neurological diseases. J Neuroimaging. 2004;14:303-313. (Pubitemid 39331612)
126. Horsfield MA, Barker GJ, Barkhof F, et al. Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging. 2003;17:389-397. (Pubitemid 36396940)
127. van Buchem MA, McGowan JC, Grossman RI. Magnetization transfer histogram methodology: its clinical and neuropsycholo-gical correlates. Neurology. 1999;53:S23-S28. (Pubitemid 29445038)
128. Henkelman RM, Stanisz GJ, Graham SJ. Magnetization transfer in MRI: a review. NMR Biomed. 2001;14:57-64. (Pubitemid 32401348)
129. van Buchem MA, Udupa JK, McGowan JC, et al. Global volumetric estimation of disease burden in multiple sclerosis based on magnetization transfer imaging. AJNR Am J Neuror-adiol. 1997;18:1287-1290. (Pubitemid 30417709)
130. Deloire-Grassin MS, Brochet B, Quesson B, et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci. 2000;178:10-16.
131. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56:407-415. (Pubitemid 39166560)
132. Rademacher J, Engelbrecht V, Burgel U, et al. Measuring in vivo myelination of human white matter fiber tracts with magnetiza¬tion transfer MR. Neuroimage. 1999;9:393-406. (Pubitemid 29369859)
133. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol. 2008;63:254-262. (Pubitemid 351355304)
134. Chen JT, Collins DL, Freedman MS, et al. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage. 2005;25:1272-1278. (Pubitemid 40591668)
135. Rovaris M, Agosta F, Sormani MP, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain. 2003;126: 2323-2332. (Pubitemid 37432375)
136. Laule C, Vavasour IM, Whittall KP, et al. Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol. 2003;250:924-931. (Pubitemid 37041022)
137. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995;45:478-482.
138. Filippi M, Rocca MA, Minicucci L, et al. Magnetization transfer imaging of patients with definite MS and negative conventional MRI. Neurology. 1999;52:845-848. (Pubitemid 29120194)
139. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809-814. (Pubitemid 28280225)
140. Goodkin DE, Rooney WD, Sloan R, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology. 1998;51:1689-1697. (Pubitemid 28565254)
141. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52:588-594. (Pubitemid 29075609)
142. Agosta F, Rovaris M, Pagani E, et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129:2620-2627. (Pubitemid 44522095)
143. Mottershead JP, Schmierer K, Clemence M, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis: a post-mortem study of the spinal cord. J Neurol. 2003;250: 1293-1301. (Pubitemid 37456888)
144. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120(Pt 7):1149-1161. (Pubitemid 27285734)
145. Boorstein JM, Moonis G, Boorstein SM, et al. Optic neuritis: imaging with magnetization transfer. AJR Am J Roentgenol. 1997;169:1709-1712 (Pubitemid 127469808)
146. Lycklama A, Nijeholt GJ, Castelijns JA, Lazeron RH, et al. Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability. J Neuroimaging. 2000;10:67-72. (Pubitemid 30225298)
147. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol. 1994;36:62-67. (Pubitemid 24205825)
148. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproduci-bility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol. 1997;244:266-270. (Pubitemid 27156478)
149. van Waesberghe JH, van Buchem MA, Filippi M, et al. MR outcome parameters
150. Filippi M, Rocca MA, Horsfield MA, et al. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetiza¬tion transfer lesion loads. J Neurol Sci. 1998;158:203-208. (Pubitemid 28342085)
151. Laule C, Vavasour IM, Moore GR, et al. Water content and myelin water fraction in multiple sclerosis: a T2 relaxation study. J Neurol. 2004;251:284-293. (Pubitemid 38387145)
152. MacKay A, Whittall K, Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med. 1994;31:673-677. (Pubitemid 24166822)
153. Moore GR, Leung E, MacKay AL, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology. 2000;55:1506-1510.
154. Vavasour IM, Laule C, Li DK, et al. Longitudinal changes in myelin water fraction in two MS patients with active disease. J Neurol Sci. 2009;276:49-53.
155. Oh J, Han ET, Lee MC, et al. Multislice brain myelin water fractions at 3 T in multiple sclerosis. J Neuroimaging. 2007;17: 156-163. (Pubitemid 46624152)
156. Stejskal EO, Tanner JE. Spin Echoes in the presence of a time-dependent field gradient. J Chem Phys. 1965;42:288-292.
157. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217:331-345.
158. Albers GW, Lansberg MG, Norbash AM, et al. Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients. Neurology. 2000;54:1562-1567. (Pubitemid 30226797)
159. Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage. 2005;26:132-140.
160. Sun SW, Liang HF, Trinkaus K, et al. Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med. 2006;55: 302-308. (Pubitemid 43238098)
161. Werring DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain. 2000;123(Pt 8): 1667-1676. (Pubitemid 30481190)
162. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci. 2002;195:103-109. (Pubitemid 34202286)
163. Maldjian JA, Grossman RI. Future applications of DWI in MS. J Neurol Sci. 2001;186(suppl 1):S55-S57.
164. Pagani E, Filippi M, Rocca MA, et al. A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage. 2005; 26:258-265. (Pubitemid 40602905)
165. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129-153. (Pubitemid 30414704)
166. Narayana PA. Magnetic resonance spectroscopy in the monitor¬ing of multiple sclerosis. J Neuroimaging. 2005;15:46S-57S. (Pubitemid 43010531)
167. Inglese M, Grossman RI, Filippi M. Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution. J Neuroima-ging. 2005;15:22S-29S. (Pubitemid 43010529)
168. Tartaglia MC, Arnold DL. The role of MRS and fMRI in multiple sclerosis. Adv Neurol. 2006;98:185-202.
169. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128:1016-1025. (Pubitemid 40675457)
170. Vrenken H, Barkhof F, Uitdehaag BM, et al. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med. 2005;53: 256-266. (Pubitemid 40171039)
171. Geurts JJ, Reuling IE, Vrenken H, et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med. 2006;55:478-483. (Pubitemid 43352544)
172. Narayanan S, Francis SJ, Sled JG, et al. Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. Neuroimage. 2006;29:637-642. (Pubitemid 43063319)
173. Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage. 2004;21:1825-1829. (Pubitemid 38446603)
174. Arnold DL, Matthews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol. 1992;31:235-241.
175. Tong KA, Ashwal S, Obenaus A, et al. Susceptibility-weighted MR imaging: a review of clinical applications in children. AJNR Am J Neuroradiol. 2008;29:9-17.
176. Sehgal V, Delproposto Z, Haacke EM, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging. 2005;22:439-450. (Pubitemid 41416402)
177. Mittal S, Wu Z, Neelavalli J, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol. 2009;30:232-252.
178. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004;52:612-618. (Pubitemid 39108975)
179. Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol. 2009;30:19-30.
180. Thomas B, Somasundaram S, Thamburaj K, et al. Clinical applications of susceptibility weighted MR imaging of the brain-a pictorial review. Neuroradiology. 2008;50: 105-116. (Pubitemid 351171454)
181. Ge Y, Zohrabian VM, Osa EO, et al. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging. 2009;29: 1190-1194.
182. Zivadinov R, Schirda C, Dwyer MG, et al. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. Int Angiol. 2010;29:158-175.
183. Ge Y, Zohrabian VM, Grossman RI. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol. 2008;65:812-816. (Pubitemid 351831461)
184. Hammond KE, Lupo JM, Xu D, et al. Development of a robust method for generating 7.0T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage. 2008;39:1682-1692.
185. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging. 2009;29:537-544.
186. Ge Y, Grossman RI, Babb JS, et al. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol. 2002; 23:1327-1333. (Pubitemid 35033881)
187. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595-605. (Pubitemid 43278222)
188. Buckle GJ. Functional magnetic resonance imaging and multiple sclerosis: the evidence for neuronal plasticity. J Neuroimaging. 2005;15:82S-93S. (Pubitemid 43010534)
189. Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain. 2000;123(Pt 11):2314-2320.
190. Parry AM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain. 2003;126:2750-2760. (Pubitemid 37463093)